Endoscopic treatments of obesity: a comprehensive review

Neylan, Christopher J.; Dempsey, Daniel T.; Tewksbury, Colleen; Williams, Noel N.; Dumon, Kristoffel R.

doi:10.1016/j.soard.2016.02.006

Cited by 25 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Full Sense Bariatric Device (Baker, Michigan) is an endoscopically placed stent that traverses the gastroesophageal junction (GEJ) and places pressure on the distal esophagus and gastric cardia to induce satiety. This temporary metal device has not yet been studied in randomized controlled clinical trials and is not FDA approved …”

Section: Non‐space‐occupying Therapiesmentioning

confidence: 99%

Endoscopic bariatric and metabolic therapies: Another tool for the management of diabetes and obesity

Chablaney

Kumta

2019

Journal of Diabetes

View full text Add to dashboard Cite

Endoscopic bariatric and metabolic therapies (EBMTs) have sparked significant interest as minimally invasive therapeutic options for weight loss. Although bariatric surgery remains an effective option for sustained weight loss and improvement in the metabolic syndrome, access and utilization are limited. Various EBMTs have been designed to emulate the physiologic effects of established surgical interventions, including space‐occupying and non‐space‐occupying gastric therapies, gastric remodeling procedures, and small bowel therapies. This review discusses the safety and efficacy of available US Food and Drug Administration‐approved minimally invasive endoscopic bariatric interventions, as well as those currently under investigation. In addition, the role of endoscopic revision after failed surgical intervention is discussed.

show abstract

Section: Non‐space‐occupying Therapiesmentioning

confidence: 99%

Endoscopic bariatric and metabolic therapies: Another tool for the management of diabetes and obesity

Chablaney

Kumta

2019

Journal of Diabetes

View full text Add to dashboard Cite

show abstract

“…335 Bariatric surgery in liver transplantation may be performed more frequently in the future in patients with earlystage liver disease, to reduce weight-related CVE; however, the efficacy of this approach requires verification by welldesigned clinical studies. 354 Noninvasive endoscopic techniques, such as use of the endobarrier, 355,356 may be effective and safer alternative approaches but their role in transplant recipients has to be assessed.…”

Section: Lifestyle Changesmentioning

confidence: 99%

Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients

et al. 2017

View full text Add to dashboard Cite

Short-term patient and graft outcomes continue to improve after kidney and liver transplantation, with 1-year survival rates over 80%; however, improving longer-term outcomes remains a challenge. Improving the function of grafts and health of recipients would not only enhance quality and length of life, but would also reduce the need for retransplantation, and thus increase the number of organs available for transplant. The clinical transplant community needs to identify and manage those patient modifiable factors, to decrease the risk of graft failure, and improve longer-term outcomes. COMMIT was formed in 2015 and is composed of 20 leading kidney and liver transplant specialists from 9 countries across Europe. The group's remit is to provide expert guidance for the long-term management of kidney and liver transplant patients, with the aim of improving outcomes by minimizing modifiable risks associated with poor graft and patient survival posttransplant. The objective of this supplement is to provide specific, practical recommendations, through the discussion of current evidence and best practice, for the management of modifiable risks in those kidney and liver transplant patients who have survived the first postoperative year. In addition, the provision of a checklist increases the clinical utility and accessibility of these recommendations, by offering a systematic and efficient way to implement screening and monitoring of modifiable risks in the clinical setting. 12 Department of Gastroenterology and Hepatology, Erasmus MC, University Hospital Rotterdam, the Netherlands. 13 Department of Gastroenterology and Hepatology, University Hospitals KU Leuven, Belgium.14 Abdominal Transplant Surgery, Microbiology and Immunology Department, University Hospitals KU Leuven, Belgium. 15 Department of Hepatology and Liver Transplantation, Reina Sofía University Hospital, IMIBIC, CIBERehd, Spain. www.transplantjournal.com S1 S olid organ transplantation has evolved from an experimental procedure to an established treatment option for many types of end-stage organ failure. Both patient and graft outcomes are continuing to improve, and 1-year patient and graft survival currently exceed 80%.1,2 However, survival rates gradually decline over the long term. In kidney transplant, 5-and 10-year graft survival rates in Europe are 77% and 56%, and for liver transplant, 64% and 54% (Figures 1 and 2). 3,4 Although most European countries have seen an increase in both living and deceased donation, transplantation is not available to all who would benefit from the procedure, and there is considerable morbidity and mortality for those listed for transplant.6 Therefore, maximizing long-term graft survival and reducing the need for retransplantation is paramount, not only in improving outcomes for the recipients but also for those awaiting a graft. The improvement in outcomes is predominantly due to reduction in (Transplantation. 2017;101:S1-S41). The authors were approached by Astellas to discuss the practical implementation o...

show abstract

“…Currently, the balloons are required, per FDA guidance, to be removed after 6 months because of concern that they slowly deflate and migrate, causing complications such as obstruction. At the time of removal, there has been up to 30%–50% mean EWL [31]. One such balloon, the BioEnterics Intragastric Balloon (Inamed Corp., Santa Barbara, CA, USA), now known as the Orbera balloon (Obalon Therapeutics, Carlsbad, CA, USA), showed a 58% ± 19% EWL at the time of removal (6 months), 39% ± 14% at 1 year, 25% ± 8% at 2 years, and 17% ± 8% at 5 years after removal [32] in a study of 122 patients.…”

Section: Endoscopic Bariatric Techniquesmentioning

confidence: 99%

“…It is left in place for 6 months. Although patients treated with the device showed a mean 32% EWL, a significant decrease in HbA 1c , and a significant decrease in antidiabetic drug requirement, the trial for this procedure was prematurely terminated because of the incidence of hepatic abscesses [31, 39]. The EndoBarrier has CE mark approval in Europe and is indicated for patients with type-2 diabetes and obesity, but is not approved for sale in the U.S. [40].…”

Section: Endoscopic Bariatric Techniquesmentioning

confidence: 99%

See 1 more Smart Citation

Current and cutting-edge interventions for the treatment of obese patients

Vairavamurthy

Cheskin

Kraitchman

et al. 2017

European Journal of Radiology

View full text Add to dashboard Cite

The number of people classified as obese, defined by the World Health Organization as having a body mass index ≥30, has been rising since the 1980s. Obesity is associated with comorbidities such as hypertension, diabetes mellitus, and nonalcoholic fatty liver disease. The current treatment paradigm emphasizes lifestyle modifications, including diet and exercise; however this approach produces only modest weight loss for many patients. When lifestyle modifications fail, the current “gold standard” therapy for obesity is bariatric surgery, including Roux-en-Y gastric bypass, sleeve gastrectomy, duodenal switch, and placement of an adjustable gastric band. Though effective, bariatric surgery can have severe short- and long-term complications. To fill the major gap in invasiveness between lifestyle modification and surgery, researchers have been developing pharmacotherapies and minimally invasive endoscopic techniques to treat obesity. Recently, interventional radiologists developed a percutaneous transarterial catheter-directed therapy targeting the hormonal function of the stomach. This review describes the current standard obesity treatments (including diet, exercise, and surgery), as well as newer endoscopic bariatric procedures and pharmacotherapies to help patients lose weight. We present data from two ongoing human trials of a new interventional radiology procedure for weight loss, bariatric embolization.

show abstract

Endoscopic treatments of obesity: a comprehensive review

Cited by 25 publications

References 41 publications

Endoscopic bariatric and metabolic therapies: Another tool for the management of diabetes and obesity

Endoscopic bariatric and metabolic therapies: Another tool for the management of diabetes and obesity

Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients

Current and cutting-edge interventions for the treatment of obese patients

Contact Info

Product

Resources

About